Activity Overview
HER2–positive (HER2+) breast cancer accounts for approximately 15% of breast cancer cases and is characterized by an increasingly complex treatment landscape. Advances in HER2-directed therapies have improved outcomes across early-stage and metastatic disease, yet the rapid expansion of available options has created challenges related to optimal sequencing, safety management, and application of emerging data for community-based clinicians, highlighting a continued educational need.
This program will be delivered as a series of 10 CME-certified virtual meetings in collaboration with ACCC-affiliated Oncology State Societies. Using an interactive, case-based format tailored to community oncology practice, the initiative is designed to translate evolving clinical evidence into practical, real-world decision-making and to support personalized care for patients with HER2+ breast cancer.
This educational activity is an archive of the live presentation
held on April 7, 2026.
Target Audience
This educational program is primarily directed toward
community-based surgical and medical oncologists, advanced practice providers,
nurses, and other health care professionals involved in the treatment of breast
cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate current and emerging clinical trial data to support evidence-based sequencing of HER2-directed therapies across stages in HER2+ breast cancer
- Integrate patient-, disease-, and treatment-related variables—including safety, tolerability, site of care, and patient goals—into personalized HER2+ breast cancer management strategies
- Analyze key safety and tolerability data for current and emerging HER2-targeted therapies to inform evidence-based patient counseling and adverse event management in HER2+ breast cancer
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and
Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, TX
Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, Menarini, Pfizer; Speaker: AstraZeneca, Daiichi Sankyo, Gilead
Jack W. Erter III, MD, MMHC
Partner/Hematologist/Oncologist
Tennessee Oncology, PLLC
Nashville, TN
Disclosures: Speaker: AstraZeneca
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.